Table 1

Demographic and predictor characteristics of cohort by VTE status

Characteristic*Group; no. (%) or mean ± SD
All patients
n = 6612
VTE in hospital
n = 106
VTE postdischarge
n = 96
Age, yr65.50 ± 12.768.56 ± 13.263.13 ± 11.9
Sex
 Female3096 (46.82)44 (41.51)37 (38.54)
 Male3516 (53.18)62 (58.49)59 (61.46)
AJCC stage
 I1718 (25.55)15 (13.64)13 (12.62)
 II2287 (34.01)27 (24.55)19 (18.45)
 III1774 (26.38)42 (38.18)45 (43.69)
 IV723 (10.75)16 (14.55)21 (20.39)
 Missing223 (3.32)10 (9.09)5 (4.85)
Grade
 1682 (10.14)6 (5.45)10 (9.71)
 23289 (48.16)45 (40.91)49 (47.57)
 31819 (27.05)37 (33.64)29 (28.16)
 4189 (2.81)7 (6.36)4 (3.88)
 Not available796 (11.84)15 (13.64)11 (10.68)
Cancer type
 Nonadenocarcinoma385 (5.72)12 (10.91)10 (9.71)
 Adenocarcinoma6340 (94.28)98 (89.09)93 (90.29)
Other complications
 No5078 (75.51)21 (19.09)62 (60.19)
 Yes1647 (24.49)89 (80.91)41 (39.81)
Surgery type
 Open5434 (80.80)96 (87.27)89 (86.41)
 Laparoscopic545 (8.10)5 (4.55)8 (7.77)
 Other746 (11.09)9 (8.18)6 (5.83)
Primary site
 Colon2135 (31.75)43 (39.09)31 (30.10)
 Rectum955 (14.20)15 (13.64)24 (23.30)
 Other gastrointestinal508 (7.55)9 (8.18)16 (15.53)
 Female genital1200 (17.84)17 (15.45)13 (12.62)
 Male genital1169 (17.38)10 (9.09)11 (10.68)
 Urinary system758 (11.27)16 (14.55)8 (7.77)
Treatment before surgery
 Chemotherapy and radiation140 (2.08)2 (1.82)5 (4.85)
 Chemotherapy181 (2.69)2 (1.82)2 (1.94)
 Radiation68 (1.01)1 (0.91)1 (0.97)
 Neither6336 (94.22)105 (95.45)95 (92.23)
RUB
 Very high2236 (33.25)94 (85.45)46 (44.66)
 High2190 (32.57)14 (12.73)36 (34.95)
 Low/moderate2299 (34.19)2 (1.82)21 (20.39)
  • AJCC = American Joint Committee on Cancer; RUB = resource utilization band; SD = standard deviation; VTE = venous thromboembolism.

  • * Accounts for multiple VTE diagnoses.

  • Denominators for tumour-specific variables are based on total number of tumours.